Microarray analysis of ~7000 genes in failing human hearts revealed altered expression of cytoskeletal and metabolic genes, including decreased SLIM1 and increased gelsolin, versus nonfailing hearts.
Observational (n=13)
BACKGROUND: Failing human hearts are characterized by altered cytoskeletal and myofibrillar organization, impaired signal transduction, abnormal protein turnover, and impaired energy metabolism. Thus, expression of multiple classes of genes is likely to be altered in human heart failure. METHODS AND RESULTS: We used high-density oligonucleotide arrays to explore changes in expression of approximately 7000 genes in 2 nonfailing and 2 failing human hearts with diagnoses of end-stage ischemic and dilated cardiomyopathy, respectively. We report altered expression of (1) cytoskeletal and myofibrillar genes (striated muscle LIM protein-1 SLIM1, myomesin, nonsarcomeric myosin regulatory light chain-2 MLC(2), and ss-actin); (2) genes responsible for degradation and disassembly of myocardial proteins (alpha(1)-antichymotrypsin, ubiquitin, and gelsolin); (3) genes involved in metabolism (ATP synthase alpha-subunit, succinate dehydrogenase flavoprotein SDH Fp subunit, aldose reductase, and TIM17 preprotein translocase); (4) genes responsible for protein synthesis (elongation factor-2 EF-2, eukaryotic initiation factor-4AII, and transcription factor homologue-HBZ17); and (5) genes encoding stress proteins (alphaB-crystallin and mu-crystallin). In 5 additional failing hearts and 4 additional nonfailing controls, we then compared expression of proteins encoded by the differentially expressed genes, alphaB-crystallin, SLIM1, gelsolin, alpha(1)-antichymotrypsin, and ubiquitin. In each case, changes in protein expression were consistent with changes in transcript measured by microarray analysis. Gelsolin protein expression was also increased in cardiomyopathic hearts from tropomodulin-overexpressing (TOT) mice and rac1-expressing (racET) mice. CONCLUSIONS: Altered expression of the genes identified in this study may contribute to development of the heart failure phenotype and/or represent compensatory mechanisms to sustain cardiac function in failing human hearts.
Yang et al. (Tue,) conducted a observational in Heart failure (n=13). High-density oligonucleotide arrays vs. Nonfailing human hearts was evaluated on Changes in gene and protein expression. Microarray analysis of ~7000 genes in failing human hearts revealed altered expression of cytoskeletal and metabolic genes, including decreased SLIM1 and increased gelsolin, versus nonfailing hearts.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: